Latest News

Shareholder Update January 2019

Jan 17th, 2019

In this issue: 

>> FDA requests further data for VivaGel® BV approval in the US

>> Launch of VivaGel® BV in multiple territories

>> VivaGel® BV licensed to ITF Pharma in the US

>> VivaGel® condom approved in Japan

>> Clinical trials for internal DEP® products progressing well

>> Patent published for AstraZeneca-DEP® drugs: DEP® Bcl2/xL inhibitors show compelling efficacy & synergy in combination

>> DEP® docetaxel & DEP® cabazitaxel outperformed both gemcitabine & Abraxane®

>> SPL7013 eye drops for viral conjunctivitis

>> Partnering activities 

>> Macquarie initiates coverage of Starpharma

>> Outlook

 Download: Shareholder Update January 2019 (pdf file, 557kb)

 

Read More

VivaGel® condom receives final regulatory approval in Japan

Jan 2nd, 2019

Melbourne, Australia; 2 January 2019: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that the VivaGel® condom has received final regulatory approval and is now able to be marketed in Japan, following the completion of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) review of the product’s medical device classification and associated data. This final approval follows on from the previously granted regulatory certification, which was attained for the VivaGel® condom.

 

Read More

US FDA requests further data for VivaGel® BV approval

Dec 27th, 2018

Melbourne, Australia: Starpharma today received advice from the US FDA that it will require confirmatory clinical data prior to approving VivaGel® BV for treatment of bacterial vaginosis (BV) and the prevention of recurrent BV (rBV).

Read More

US VivaGel® BV licensed for A$142M milestones, plus royalties

Dec 20th, 2018

Melbourne, Australia: Starpharma and ITF Pharma today announced they have signed a licence for the sales and marketing rights to VivaGel® BV in the United States. Starpharma will be eligible to receive up to US$101M (A$142M) in regulatory approval and commercialisation milestones in addition to attractive tiered royalties on sales.

Read More

In the media

Motley Fool ‘Extreme Opportunities’ Advisor Dr Anirban Mahanti covers Starpharma’s 2018 Financial Year Results

Aug 22nd, 2018

Dr Anirban Mahanti, Advisor at Motley Fool writes that FY18 was a “hugely transformative year for Starpharma”, noting the Company’s key milestones including its “smart licensing agreements” and “potentially game-changing pipeline of drugs”. Originally published on Motley Fool and republished with permission. Read the full article here

Read More

Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler for The Constant Investor

Jul 16th, 2018

Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler on online investor publication The Constant Investor, where she discussed the company’s dendrimer platform technology. To listen to fully interview, click here. (Note: paywall) Read More

Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler on Talking Business

Jul 1st, 2018

Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler about how the company has taken VivaGel® BV from discovery to market and developed commercial products with its proprietary dendrimer technology platform.

To listen to the podcast, click here.

Read More

Starpharma CEO Jackie Fairley featured on Qantas’ inflight magazine Travel Insider

Jul 1st, 2018

Starpharma CEO Dr Jackie Fairley was featured in Qantas’ inflight magazine. To read the article, click here.

Read More

Shareholder Updates

Shareholder Update January 2019

Jan 17th, 2019

In this issue: 

>> FDA requests further data for VivaGel® BV approval in the US

>> Launch of VivaGel® BV in multiple territories

>> VivaGel® BV licensed to ITF Pharma in the US

>> VivaGel® condom approved in Japan

>> Clinical trials for internal DEP® products progressing well

>> Patent published for AstraZeneca-DEP® drugs: DEP® Bcl2/xL inhibitors show compelling efficacy & synergy in combination

>> DEP® docetaxel & DEP® cabazitaxel outperformed both gemcitabine & Abraxane®

>> SPL7013 eye drops for viral conjunctivitis

>> Partnering activities 

>> Macquarie initiates coverage of Starpharma

>> Outlook

 Download: Shareholder Update January 2019 (pdf file, 557kb)

 

Read More

Shareholder Update February 2018

Feb 19th, 2018

In this issue: 

>> New sites open for the DEP® docetaxel phase 2 trial

>> DEP® cabazitaxel phase 1 / 2 trial commences

>> VivaGel® BV NDA submission lodged under Fast Track program

>> VivaGel® BV approved by TGA

>> DEP® irinotecan progressing towards the clinic

>> AstraZeneca-Starpharma collaboration

>> Extensive global licensing negotiations for VivaGel® BV

>> Positive market research findings for VivaGel® BV 

>> Q2 Cashflow Report at 31 December 2017

>> OTCQX market recognition

>> Starpharma News & Events

>> Outlook

 Download: Shareholder Update February 2018 (pdf file, 1.5mb)

Read More

Sign up to receive news here